Ustekinumab 90 mg SC q12w clinical trials

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

This study looks at whether people with Crohn's disease or ulcerative colitis, who are feeling well on ustekinumab, can reduce their dose without their symptoms returning. Researchers want to see if less frequent injections still keep the disease under control.